Literature DB >> 9177441

No concomitant occurrence of the N-ras and p53 gene mutations in myelodysplastic syndromes.

K Mitani1, A Hangaishi, N Imamura, K Miyagawa, S Ogawa, Y Kanda, Y Yazaki, H Hirai.   

Abstract

Mutations of the N-ras oncogene and p53 tumor suppressor gene were simultaneously investigated in bone marrow cells from 44 patients with myelodysplastic syndrome (MDS) or MDS-derived leukemia by single-strand conformation polymorphism (SSCP) analysis followed by direct sequencing. The mutations of the N-ras gene were detected only in two cases with MDS-derived leukemia. Three patients with MDS-derived leukemia and one with refractory anemia with excess of blasts exhibited five mutations of the p53 gene. No concomitant mutations of both genes were observed in our study, suggesting that alterations of both genes could play an important role in the progression of MDS in a non-cooperative manner.

Entities:  

Mesh:

Year:  1997        PMID: 9177441     DOI: 10.1038/sj.leu.2400666

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  Study of p53 in elderly patients with myelodysplastic syndromes by immunohistochemistry and DNA analysis.

Authors:  M Kikukawa; N Aoki; Y Sakamoto; M Mori
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

2.  Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Authors:  Hideki Muramatsu; Hideki Makishima; Anna M Jankowska; Heather Cazzolli; Christine O'Keefe; Nao Yoshida; Yinyan Xu; Nobuhiro Nishio; Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Koji Kato; Atsushi Manabe; Seiji Kojima; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

3.  Low-level expression of ETV6/TEL in patients with Myelodysplastic syndrome.

Authors:  Tetsuya Yamagata; Yuka Nakamura; Kinuko Mitani
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

4.  Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.

Authors:  Aref Al-Kali; Alfonso Quintás-Cardama; Raja Luthra; Carlos Bueso-Ramos; Sherry Pierce; Tapan Kadia; Gautam Borthakur; Zeev Estrov; Elias Jabbour; Stefan Faderl; Farhad Ravandi; Jorges Cortes; Ayalew Tefferi; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2013-03-20       Impact factor: 10.047

5.  Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.

Authors:  Yuka Sugimoto; Mikkael A Sekeres; Hideki Makishima; Fabiola Traina; Valeria Visconte; Anna Jankowska; Andres Jerez; Hadrian Szpurka; Christine L O'Keefe; Kathryn Guinta; Manuel Afable; Ramon Tiu; Kathy L McGraw; Alan F List; Jaroslaw Maciejewski
Journal:  J Hematol Oncol       Date:  2012-03-05       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.